Picture1Sanuwave4

SANUWAVE will host a conference call to present Q3 2023 financial results on November 10, 2023 at 8:00 AM (ET)

 

EDEN PRAIRIE, Minn., November 8, 2023 (GLOBE NEWSWIRE) — through NewMediaWire – SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation wound care products, will host a live conference call to present its third quarter 2023 financial results on Friday, November 10, 2023 at 8:00 AM (ET).

Telephone access to the conversation is possible by calling the following numbers:

Participant Listen: 1-877-407-0784 or 1-201-689-8560

Conference ID number: 13742652

OR click on the Call me™ link for direct telephone access to the event.
https://callme.viavid.com/viavid/?callme=true&passcode=13732361&h=true&info=company&r=true&B=6

Attendees can use the Guest dial-in numbers above and be answered by an operator OR click on the Call me™ link for direct telephone access to the event.

A replay is available until November 24, 2023:

Replay dial-in: 1-844-512-2921 or 1-412-317-6671

Access ID: 13742652

About SANUWAVE
SANUWAVE Health focuses on the research, development and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue and vascular structures.

SANUWAVE’s end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. SANUWAVE applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic and cardiac/endovascular conditions.

Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding financial results and plans for future business development activities, and are therefore forward-looking. Forward-looking statements include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s control. Actual results may differ materially from those projected in the forward-looking statements. Key risks, assumptions and factors that could affect the company’s results of operations, performance and financial condition include risks associated with the approval and marketing of the Company’s product candidates and products. [unproven pre-clinical] and clinical development activities, regulatory oversight, the Company’s ability to manage its capital issues, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.

CONTACT:
Investors@Sanuwave.com

Source link

Similar Posts

  • Stratus® Medical Adds Fifth US Patent and Two Canadian Patents to its 29-Patent Global IP Portfolio for the NIMBUS® Electrosurgical RF Multitined Expandable Electrode

      MAGNOLIA, Texas, Nov. 8, 2023 /PRNewswire/ — Stratus® Medical, a company focused on improving clinical outcomes for chronic pain patients by advancing radiofrequency (RF) technology for the treatment of pain, today announced the issuance of its fifth U.S. patent (U.S. Patent No. 11,806,070 ) and the first two Canadian patents (Canadian patent). Nos. 2,778,997…

  • |

    DVT after knee surgery

    What if the biggest threat to your recovery isn’t the orthopedic procedure itself, but a silent complication that can strike without warning? Deep vein thrombosis is a serious medical concern. It affects approximately 600,000 Americans each year. We recognize that undergoing a major joint operation requires careful attention to potential complications. DVT after knee surgery prevention Our goal is to provide a clear guide on managing this specific risk. Understanding how a dangerous clot forms in the leg is the vital first step. This knowledge empowers you during the post-operative period. We emphasize that proactive management of your health is essential. By following expert-led advice, you can take control. This effort minimizes chances of a serious vascular issue and supports a smoother healing journey. Key Takeaways Deep vein thrombosis is a common but serious risk following major orthopedic procedures. Proactive health management is crucial for a safe post-operative period. Understanding how blood clots form is the first step in prevention. Expert guidance can help you minimize dangers and take control of your healing process. A smooth recovery involves being aware of potential complications from the start. Simple, informed actions can significantly reduce your personal risk. Understanding the Risk of DVT After Knee Surgery Why does a procedure focused on improving mobility simultaneously increase the chance of a dangerous blockage? We must explore the nature of the threat and the specific factors a major operation introduces. What is Deep Vein Thrombosis? This condition involves a blood clot forming in a deep vein, usually in the leg. If such a clot breaks free, it can travel to the lungs. This causes a life-threatening pulmonary embolism. We note that approximately 600,000 Americans are affected each year. It is a critical concern following any major joint replacement. deep vein thrombosis risk factors Why Knee Surgery Increases the Clot Risk Several factors converge during a knee replacement. The body’s natural healing response can make blood more likely to clot. Reduced mobility after the procedure slows circulation in the legs. The risk is highest from two to ten days post-operation. Patients remain at risk for about three months. Without preventative care, studies show blood clot rates of 40-60%. Even with modern care, 18-20% of joint replacement patients may still develop a clot. This highlights the need to watch for swelling in the leg. Timeframe Risk Level Key Data Initial High-Risk Period Highest 2 to 10 days after surgery Extended Risk Period Elevated Up to 3 months post-operation Without Prevention Very High 40-60% clot rate in major orthopedic surgery With Modern Protocols Significant 18-20% of knee replacement patients Prevention and Treatment Approaches Managing the threat of post-operative clots involves a dual strategy of medication and mechanical aids. We focus on keeping your circulation strong during the healing phase. This two-part defense significantly lowers your personal danger. Medication and Anti-Clotting Therapies We often prescribe specific drugs to reduce your body’s ability to form dangerous masses. Options include injections like Heparin or daily pills such as Warfarin. Newer direct oral anticoagulants offer convenient pill-based therapy. Your doctor selects the best type based on your health profile. anti clotting medication and compression…

  • Put down the drink; Alcohol use after a concussion can prolong symptoms in collegiate athletes

    Alcohol use after injury is associated with prolonged recovery from concussion in NCAA athletes Chang RC, Singleton M, Chrisman SPD, et al. Alcohol use after injury is associated with prolonged recovery from concussion in NCAA athletes. Clin J Sport Med. Published online 2023:1-8. doi:10.1097/JSM.0000000000001165 https://journals.lww.com/cjsportsmed/Abstract/9900/Postinjury_Alcohol_Use_Is_Associated_With.142.aspx Take home message Collegiate athletes can experience long-lasting concussion symptoms…

  • Medacta announces the launch of GMK SpheriKA, the world’s first knee implant optimized for kinematic alignment (KA)

      Castel San Pietro, October 30, 2023 – Medacta Group SA (“Medacta”, SIX: MOVE), a Swiss company providing innovative, personalized and sustainable solutions for joint replacement, sports medicine and spine surgery, is pleased to announce the launch of GMK SpheriKA, the world’s first KA-optimized femoral component indicated for total knee replacement. GMK SpheriKA will make…

  • Many patients with autoimmune diseases struggle with diagnosis, costs, and inattentive care

      After years of debilitating bouts of fatigue, Beth VanOrden thought she finally had an answer to her problems in 2016 when she was diagnosed with Hashimoto’s disease, an autoimmune disease. For her and millions of other Americans, that’s the most common cause of hypothyroidism, a condition in which the thyroid, a butterfly-shaped gland in…

Leave a Reply

Your email address will not be published. Required fields are marked *